HC Wainwright Cuts Personalis (NASDAQ:PSNL) Price Target to $8.00

Personalis (NASDAQ:PSNL) had its price objective decreased by HC Wainwright from $11.00 to $8.00 in a research note issued to investors on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($1.36) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.39) EPS, FY2028 earnings at ($0.05) EPS and FY2029 earnings at $0.35 EPS.

A number of other research firms have also issued reports on PSNL. Needham & Company LLC reiterated a “buy” rating and set a $7.25 price objective on shares of Personalis in a research note on Wednesday, January 8th. Lake Street Capital upped their price target on Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th.

Personalis Stock Performance

PSNL stock opened at $5.01 on Monday. The stock has a fifty day moving average of $4.93 and a 200-day moving average of $4.75. Personalis has a fifty-two week low of $1.12 and a fifty-two week high of $7.20. The company has a market capitalization of $353.95 million, a price-to-earnings ratio of -2.98 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last posted its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). The business had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. During the same quarter in the previous year, the business earned ($0.51) EPS. Equities analysts predict that Personalis will post -1.37 EPS for the current year.

Institutional Investors Weigh In On Personalis

Several large investors have recently added to or reduced their stakes in the business. abrdn plc purchased a new stake in shares of Personalis in the 4th quarter valued at about $1,722,000. China Universal Asset Management Co. Ltd. purchased a new stake in Personalis in the fourth quarter valued at approximately $87,000. SG Americas Securities LLC bought a new stake in Personalis during the fourth quarter valued at approximately $63,000. Barclays PLC grew its stake in Personalis by 45.4% in the 3rd quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after buying an additional 20,444 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Personalis by 20.0% in the 3rd quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock worth $2,683,000 after buying an additional 83,068 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.